Cardiac 123I-MIBG scintigraphy in heart failure.
This review focuses on myocardial [(123)I]mIBG imaging in patients with cardiomyopathy and heart failure (HF). In particular, the potential role of myocardial (123)I-mIBG scintigraphy in the prediction of potentially fatal arrhythmic events is described. A growing body of evidence supports the use of cardiac sympathetic innervation imaging, specifically using (123)I-mIBG, to risk stratify patients with HF. Cardiac sympathetic imaging can help to improve understanding of the mechanisms responsible for increased sympathetic activity in HF, and how sympathetic over-activity exerts its deleterious actions. Eventually, this may result in more effective therapies and, thereby, better outcome for these patients. Assessment of cardiac sympathetic activity could also contribute to a more appropriate selection of individual patients for implantable cardioverter-defibrillators (ICD).
Agostini
D
D
CHU Cote de Nacre, Caen, France. agostini-de@chu-caen.fr
Verberne
H J
HJ
Hamon
M
M
Jacobson
A F
AF
Manrique
A
A
D019797:3-Iodobenzylguanidine; D006321:Heart / Q000000981:diagnostic imaging*; D006333:Heart Failure / Q000175:diagnosis / Q000000981:diagnostic imaging* / Q000628:therapy; D006801:Humans; D009206:Myocardium / Q000473:pathology; D011379:Prognosis; D011446:Prospective Studies; D011877:Radionuclide Imaging
D019797:3-Iodobenzylguanidine